title: [Chronotherapy with 5-fluorouracil folinic acid and oxaliplatin delivered over 48 hours every second week in colorectal cancer. The CHC-Liège experience (Belgium)].
abstract: One hundred and ten consecutive patients suffering from a colorectal cancer received chronotherapy infused over two days every two weeks. Each course comported 5 FU 3g/m(2), folinic acid (600 mg/m(2) - l. form or 1200 mg/m(2)--racemic form) and oxaliplatin (85/mg/m(2)--adjuvant indication or 100mg/m(2)--palliative indication). According to chronobiological concepts, 5 FU and folinic acid were infused from 10 pm to 10 am with a peak at 4 am while oxaliplatin was delivered from 10 am to 10 pm with a peak at 4 pm. The overall tolerance was excellent with a maximum of 17% patients experiencing a grade 3 toxicity. The toxicity was higher in women, in older patients (>=70) or in case of flat infusion. In adjuvant situation (60 cases), progression free and overall survivals established respectively at 76% (42+months) and 88% (45+months). Fifty-two percent response rate were recorded within the palliative group (50 cases) with an overall 68% disease control. Median progression free survival was seven months but median survival was not attained at 31+ months. Thirty percent patients could benefit from a curative surgery after chemotherapy. Older patients (>=70) experienced worsened survival. In conclusion, we think that our chrono-FOLFOX 2-12 should be proposed as standard treatment for colorectal cancer patients.
authors.affiliation: CHC-Liège, Clinique Saint-Joseph, rue de Hesbaye 75, 4000 Liège, France. Electronic address: christian.focan@chc.be.
authors.forename: C
authors.initials: C
authors.lastname: Focan
authors.forename: G
authors.initials: G
authors.lastname: Demolin
authors.forename: F
authors.initials: F
authors.lastname: Kreutz
authors.forename: M-P
authors.initials: MP
authors.lastname: Graas
authors.forename: L
authors.initials: L
authors.lastname: Longrée
authors.forename: G
authors.initials: G
authors.lastname: Matus
authors.forename: N
authors.initials: N
authors.lastname: Moeneclaey
authors.forename: D
authors.initials: D
authors.lastname: Focan-Henrard
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D019454:Chronotherapy / Q000009:adverse effects / Q000379:methods*; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage* / Q000009:adverse effects; D000077150:Oxaliplatin; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D002955:Leucovorin; D005472:Fluorouracil
keywords: Cancer colorectal; Chronotherapy; Chronothérapie; Colorectal cancer; Oxaliplatin; Oxaliplatine